Mark W. HahnChief Financial Officer (919) email@example.com As part of the agreement, an indirect subsidiary of Sobi will launch a takeover bid on all outstanding Dova shares, with a down payment of $27.50 in cash and a non-tradable CVR of $1.50 per share. The non-negotiable CVR is paid for the processing of CITs after the administrative authorization of DOPTELET. There can be no assurance that such authorization will be granted or that a conditional payment will be made. Dova will make a recommendation to shareholders that they recommend selling your shares to Sobi, subject to the terms of the final merger agreement. Some of the company`s major shareholders, including Paul B. Manning, who represents the majority of the outstanding shares, have entered into a tender and support agreement in which they are required to tender for their shares in the offer. The transaction is subject to customary closing conditions, including the tendering of more than 50% of all Dova shares that are pending upon the expiry of the offer and the end of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act. news.cision.com/swedish-orphan-biovitrum-ab/r/sobi-successfully-completes-tender-offer-for-all-outstanding-shares-of-dova-pharmaceuticals,c2957973 DURHAM, N.C., September 30, 2019 (NEWS GLOBEWIRE) — Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) announced today that it will launch an agreement and a proposed merger with Sweden`s Orphan Biovitrum (SOBI) (OM: In accordance with the agreement, an indirect subsidiary of Sobi will launch an offer to purchase all of Dova`s outstanding shares, offering Dova shareholders a $27.50 in cash deposit. DOPTELET`s administrative approval is an additional $1.50 cash share for the treatment of chemotherapy-induced thrombopenia (CIT), which corresponds to a potential total potency of $29.00 per share or a total potential pot of up to $915 million on a fully diluted basis. View original content:www.prnewswire.com/news-releases/sobi-successfully-completes-acquisition-of-dova-pharmaceuticals-300956404.html Guido Oelkers, PhD, President and Chief Executive Officer of Sobi, commented: «The pace of upcoming launches and admissions in all the indications and regions that Doptelet provides allows us to further accelerate the growth of our haematological franchise.
There is a great unrealized medical need in thrombocytopenia, and for us, this is a great opportunity to give patients access to new and improved treatments. We are also pleased to welcome Dova`s 125 professionals who will significantly strengthen Sobi`s hematology infrastructure and expand our value chain in the United States. At Sobi, we are changing the lives of people affected by rare diseases. As an international biopharmaceutical specialist company, we offer sustainable access to innovative therapies in the fields of hematology, immunology and specialized care.